TTFields In Germany in routine clinical care

Not Applicable

Completed

• Conditions: Glioblastoma; Cancer

• Registration Number: ISRCTN14267833
• Lead Sponsor: ovocure GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-08-08
• Study Completion: 2022-08-31
• Last Update Posted: 6 March 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 709

Inclusion Criteria

1. Newly diagnosed histologically confirmed GBM (WHO-Grade IV)
2. Patient within first 3 cycles of first-line tumor-specific maintenance chemotherapy
3. = 18 years of age
4. Clinical indication for TTFields treatment
5. Given informed consent for use and processing of data

Exclusion Criteria

1. Present or planned pregnancy
2. Significant additional neurological disease (e.g. significantly increased intracerebral pressure (ICP) with a significant midline shift of the brain)
3. Active implanted medical device (e.g. deep brain stimulator)
4. Documented allergy to conductive hydrogel
5. Skull defect (e.g. missing bone with no replacement, bullet fragments in the skull)

Study & Design

• Study Type: Observational
• Study Design: Not specified